Synergistic activity of polymyxin B combined with vancomycin against carbapenem-resistant and polymyxin-resistant Acinetobacter baumannii: first in vitro study

References

1. Rynga D, Shariff M, Deb M. Phenotypic and molecular characterization of clinical isolates of Acinetobacter baumannii isolated from Delhi, India. Ann Clin Microbiol Antimicrob 2015; 14:40 [View Article]
   [Google Scholar]
2. Lemos EV, de la Hoz FP, Einarson TR, McGhan WF, Quevedo E et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect 2014; 20:416–423 [View Article]
   [Google Scholar]
3. Jeannot K, Bolard A, Plésiat P. Resistance to polymyxins in Gram-negative organisms. Int J Antimicrob Agents 2017; 49:526–535 [View Article]
   [Google Scholar]
4. Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs 2014; 74:1315–1333 [View Article]
   [Google Scholar]
5. Kaye KS, Pogue JM, Tran TB, Nation RL, Li J. Agents of last resort polymyxin resistance. Infect Dis Clin N Am 2016; 30:391–414
   [Google Scholar]
6. Neu H. C, Gootz T. D. Antimicrobial chemotherapy. In Baron S. Medical Microbiology, 4th ed.. Galveston: Univ. Texas Med. Branch; 1996163–185
   [Google Scholar]
7. Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54:5316–5322 [View Article]
   [Google Scholar]
8. Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod or chalk and cheese?. Clin Infect Dis 2014; 59:88–94
   [Google Scholar]
9. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, 28th ed. CLSI supplement M100 Wayne, PA: Clinical and Laboratory Standards Institute; 2018
   [Google Scholar]
10. Menegucci TC, Albiero J, Migliorini LB, Alves JL, Viana GF et al. Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections. Int J Antimicrob Agents 2016; 47:380–385 [View Article]
    [Google Scholar]
11. Clinical and Laboratory Standards Institute Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard Document M07-A10 , 10th ed. Wayne, PA: 2015
    [Google Scholar]
12. Moody J. Synergism testing: broth microdilution, checkerboard and broth macrodilution methods. In Garcia L. S, Isenberg H. D. Clinical Microbiology Procedures Handbood, 2nd ed. Washington, DC: ASM Press; 20075.12.1–5.12.5
    [Google Scholar]
13. Klepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob Agents Chemother 1998; 42:1207–1212 [View Article]
    [Google Scholar]
14. Sopirala MM, Mangino JE, Gebreyes WA, Biller B, Bannerman T et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54:4678–4683 [View Article]
    [Google Scholar]
15. Drieux L, Brossier F, Sougakoff W, Jarlier V. Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide. Clin Microbiol Infect 2008; 14:90–103 [View Article]
    [Google Scholar]
16. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016; 16:161–168 [View Article]
    [Google Scholar]
17. Zhanel GG, Mayer M, Laing N, Adam HJ. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50:2228–2230 [View Article]
    [Google Scholar]
18. Yang H, Lv N, Hu L, Liu Y, Cheng J et al. In vivo activity of vancomycin combined with colistin against multidrug-resistant strains of Acinetobacter baumannii in a Galleria mellonella model. Infect Dis (Lond) 2016; 48:189–194 [View Article]
    [Google Scholar]
19. O'Hara JA, Ambe LA, Casella LG, Townsend BM, Pelletier MR et al. Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother 2013; 57:2103–2108 [View Article]
    [Google Scholar]
20. Foweraker JE, Laughton CR, Brown DF, Bilton D. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis. Antimicrob Agents Chemother 2009; 53:4809–4815 [View Article]
    [Google Scholar]
21. Percin D, Akyol S, Kalin G. In vitro synergism of combinations of colistin with selected antibiotics against colistin-resistant Acinetobacter baumannii. GMS Hyg Infect Control 2014; 9:Doc14 [View Article]
    [Google Scholar]
22. Bae S, Kim MC, Park SJ, Kim HS, Sung H et al. In-vitro synergistic activity of antimicrobial agents in combination against clinical isolates of colistin-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2016; 60:6774–6779 [View Article]
    [Google Scholar]
23. Leite GC, Oliveira MS, Perdigão-Neto LV, Rocha CK, Guimarães T et al. Antimicrobial combinations against pan-resistant Acinetobacter baumannii isolates with different resistance mechanisms. PLoS One 2016; 11:e0151270 [View Article]
    [Google Scholar]
24. Grabowicz M, Andres D, Lebar MD, Malojčić G, Kahne D et al. A mutant Escherichia coli that attaches peptidoglycan to lipopolysaccharide and displays cell wall on its surface. Elife 2014; 3:e05334 [View Article]
    [Google Scholar]
25. Henry R, Vithanage N, Harrison P, Seemann T, Coutts S et al. Synergistic interactions of vancomycin with different antibiotics against Escherichia coli: trimethoprim and nitrofurantoin display strong synergies with vancomycin against wild-type E. coli. Antimicrob Agents Chemother 2012; 56:59–69
    [Google Scholar]
26. Boll JM, Crofts AA, Peters K, Cattoir V, Vollmer W et al. A penicillin-binding protein inhibits selection of colistin-resistant, lipooligosaccharide-deficient Acinetobacter baumannii. Proc Natl Acad Sci USA 2016; 113:E6228–E6237 [View Article]
    [Google Scholar]
27. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45:433–438 [View Article]
    [Google Scholar]
28. Cai Y, Lee W, Kwa AL. Polymyxin B versus colistin: an update. Expert Rev Anti Infect Ther 2015; 13:1481–1497 [View Article]
    [Google Scholar]
29. Soares DS, Reis ADF, Silva Junior GBD, Leite TT, Parente Filho SLA et al. Polymyxin-B and vancomycin-associated acute kidney injury in critically ill patients. Pathog Glob Health 2017; 111:137–142 [View Article]
    [Google Scholar]
30. Garnacho-Montero J, Amaya-Villar R, Gutiérrez-Pizarraya A, Espejo-Gutiérrez de Tena E, Artero-González ML et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy 2013; 59:225–231 [View Article]
    [Google Scholar]
31. Kalin G, Alp E, Coskun R, Demiraslan H, Gündogan K et al. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?. J Infect Chemother 2012; 18:872–877 [View Article]
    [Google Scholar]
32. Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B?. Antimicrob Agents Chemother 2017; 61:e02319–16 [View Article]
    [Google Scholar]
33. Sampson TR, Liu X, Schroeder MR, Kraft CS, Burd EM et al. Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway. Antimicrob Agents Chemother 2012; 56:5642–5649 [View Article]
    [Google Scholar]
34. Zhou A, Kang TM, Yuan J, Beppler C, Nguyen C et al. Synergistic interactions of vancomycin with different antibiotics against Escherichia coli: trimethoprim and nitrofurantoin display strong synergies with vancomycin against wild-type E. coli. Antimicrob Agents Chemother 2015; 59:276–281 [View Article]
    [Google Scholar]